Rational Design of the Spatial Effect in a Fe(II)/α‐Ketoglutarate‐Dependent Dioxygenase Reverses the Regioselectivity of C(sp³)−H Bond Hydroxylation in Aliphatic Amino Acids

Article

Author: Yin, Dejing ; Zheng, Chenni ; Wu, Jing ; Wang, Ran ; Gao, Cong ; Wen, Jian ; Song, Wei ; Chen, Xiulai ; Wei, Wanqing ; Liu, Liming ; Liu, Jia

AbstractThe hydroxylation of remote C(sp3)−H bonds in aliphatic amino acids yields crucial precursors for the synthesis of high‐value compounds. However, accurate regulation of the regioselectivity of remote C(sp3)−H bonds hydroxylation in aliphatic amino acids continues to be a common challenge in chemosynthesis and biosynthesis. In this study, the Fe(II)/α‐ketoglutarate‐dependent dioxygenase from Bacillus subtilis (BlAH) was mined and found to catalyze hydroxylation at the γ and δ sites of aliphatic amino acids. Crystal structure analysis, molecular dynamics simulations, and quantum chemical calculations revealed that regioselectivity was regulated by the spatial effect of BlAH. Based on these results, the spatial effect of BlAH was reconstructed to stabilize the transition state at the δ site of aliphatic amino acids, thereby successfully reversing the γ site regioselectivity to the δ site. For example, the regioselectivity of L‐Homoleucine (5 a) was reversed from the γ site (1 : 12) to the δ site (>99 : 1). The present study not only expands the toolbox of biocatalysts for the regioselective functionalization of remote C(sp3)−H bonds, but also provides a theoretical guidance for the precision‐driven modification of similarly remote C(sp3)−H bonds in complex molecules.

19 Apr 2024·Organic Letters

Chemoenzymatic Synthesis of 4,5-Dihydroxyisoleucine Fragment of α-Amanitin

Article

Author: Chao, Tsung-Han ; Renata, Hans

The ability of α-amanitin to potently inhibit RNA polymerase II (RNAP II) has elicited further research into its use as a novel payload for antibody-drug conjugates. Despite this promise, the de novo synthesis of α-amanitin is still a major challenge as it possesses an unusual bicyclic octapeptide structure that contains several oxidized amino acids, most notably 4,5-dihydroxy-l-isoleucine. Here, we report a concise chemoenzymatic synthesis of this key amino acid residue, which features two regioselective and diastereoselective enzymatic C-H oxidations on l-isoleucine.

01 Feb 2024·Molecular Catalysis

Affinity-peptide-mediated multi-enzyme self-assembly system enhances dioxygenase catalyzing C–H hydroxylation via in situ α-ketoglutarate generation and H2O2 elimination

Author: Nie, Yao ; Gu, Jie ; Xin, Shiyi ; Wu, Lunjie ; Zhao, Donglin ; Xu, Yan ; Liu, Huan

Fe(II)/α-ketoglutarate-dependent dioxygenases (Fe(II)/α-KG DOs) are powerful biocatalysts for C-H bond hydroxylation, generating diverse high-value mols.An inadequate cosubstrate α-KG supply leads to low yields of the desired products.Currently, -glutamate oxidase (LGOX) is used to generate α-KG and cascades with catalase (KatG) to eliminate H2O2 (a byproduct of LGOX), an inhibitor of Fe(II)/α-KG DOs.However, free enzymes still cause H2O2 accumulation, inhibiting Fe(II)/α-KG DO activity.Here, we employed RIAD-RIDD short peptides to form LGOX-KatG specific 1:2 ratio self-assembled tri-enzyme units using a scaffold-free strategy to obtain structural insights via computational anal. and to avoid H2O2 toxicity to achieve high yield of a promising anti-diabetic drug (2S,3R,4S)-4-hydroxyisoleucine in a one-pot system.A conversion of >95% was achieved at a 100 mM isoleucine within 7 h, with 2.00 g.L-1.h-1 space-time yield.This work provides a universal, industrially attractive approach for supplying a cosubstrate for Fe(II)/α-KG DO catalyzing hydroxylation.

100 Deals associated with ID-1101

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 2	-	BELLUS Health, Inc.	-
Obesity	Phase 2	-	BELLUS Health, Inc.	-
Obesity	Phase 2	Canada	Bellus Health (Innodia), Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

ID-1101

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation